Venue: Brussels, Belgium
Next generation sequencing and high throughput screening technologies are revolutionizing our current molecular understanding of cancer. Molecular tumor profiles can now be established at affordable cost within a timeframe compatible with clinical practice. It is anticipated, that biomarker-based patient selection will soon move to the forefront of effective cancer treatment.
Markers in Cancer, a joint meeting by ASCO, EORTC & NCI, will focus on the relevance and the feasibility of implementing emerging technologies into clinical practice.
A tutorial on biomarker development dealing with issues related to next generation trial design (5-7 November 2013) will precede the Main Meeting and is open to early career oncologists.